Munich, Germany \u2014 Ariceum Thera\u00adpeu\u00adtics (Ariceum) successfully closes a Series A expan\u00adsion finan\u00adcing, raising an addi\u00adtio\u00adnal EUR 22.75 million for Ariceum on top of the EUR 25 million Series A finan\u00adcing announ\u00adced in June 2022.<\/p>\n
With this, Ariceum, a priva\u00adtely held biotech\u00adno\u00adlogy company based in Berlin, Germany, aims to advance its clini\u00adcal pipe\u00adline of next-gene\u00adra\u00adtion radio\u00adphar\u00admaceu\u00adti\u00adcals and further expand the company, with a focus on its proprie\u00adtary peptide deri\u00adva\u00adtive sato\u00adreo\u00adtide, as well as a pipe\u00adline of other projects. New inves\u00adtors Andera Part\u00adners and Early\u00adbird Venture Capi\u00adtal <\/strong>join exis\u00adting inves\u00adtor Pureos Bioven\u00adtures<\/strong> in expan\u00adsion financing.<\/p>\n Olivier Litzka from Andera Part\u00adners and Chris\u00adtoph Mass\u00adner from Early\u00adbird Venture Capi\u00adtal become addi\u00adtio\u00adnal members of Arice\u00adum\u2019s advi\u00adsory board.<\/p>\n Baker McKen\u00adzie advi\u00adsed Ariceum Thera\u00adpeu\u00adtics on all legal aspects rela\u00adted to the finan\u00adcing. \u201cToge\u00adther with our client and our team of specia\u00adli\u00adzed corporate\/M&A and life scien\u00adces lawy\u00aders, we have succee\u00added in secu\u00adring further finan\u00adcing for Ariceum, paving the way for the deve\u00adlo\u00adp\u00adment of thera\u00adpies for pati\u00adents suffe\u00adring from certain diffi\u00adcult-to-treat cancers,\u201d commen\u00adted Julia Braun, LL.M., the lead part\u00adner on the transaction.<\/p>\n Legal advi\u00adsor Ariceum Thera\u00adpeu\u00adtics: Baker McKenzie<\/strong><\/p>\n Lead: Julia Braun (Corporate\/M&A, Part\u00adner, Munich) About Baker McKenzie<\/strong><\/p>\n Complex busi\u00adness chal\u00adlenges require a holi\u00adstic response across diffe\u00adrent markets, sectors and juris\u00addic\u00adtions. Baker McKen\u00adzie\u2019s solu\u00adti\u00adons for clients are accom\u00adpa\u00adnied by seam\u00adless advice, under\u00adpin\u00adned by in-depth prac\u00adtice and indus\u00adtry know\u00adledge as well as excel\u00adlent local market insights. In more than 70 offices world\u00adwide, we work with our clients to provide solu\u00adti\u00adons for a connec\u00adted world.<\/p>\n","protected":false},"excerpt":{"rendered":" Munich, Germany \u2014 Ariceum Thera\u00adpeu\u00adtics (Ariceum) successfully closes a Series A expan\u00adsion finan\u00adcing, raising an addi\u00adtio\u00adnal EUR 22.75 million for Ariceum on top of the EUR 25 million Series A finan\u00adcing announ\u00adced in June 2022. With this, Ariceum, a priva\u00adtely held biotech\u00adno\u00adlogy company based in Berlin, Germany, aims to advance its clini\u00adcal pipe\u00adline of next-gene\u00adra\u00ad\u00adtion radiopharmaceuticals [\u2026]<\/p>\n","protected":false},"author":2,"featured_media":48459,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"wp_typography_post_enhancements_disabled":false,"footnotes":""},"categories":[886,1364,1366,1367,1368,1369,1372,1373],"tags":[],"class_list":["post-48464","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-general-en","category-featured-en","category-news-en","category-lawyers-tax-advisors-auditors-en","category-lawyers-tax-consultants-auditors","category-investors","category-consultant","category-venture-capital-en"],"yoast_head":"\n
\nErik Kuhn (Asso\u00adciate, Munich), Anna Dzik (Asso\u00adciate, Munich)<\/p>\n